The abstract pasted below was not an April fool’s joke. To the contrary, it illustrated the increasing efforts to combine in silico and in vitro analysis to predict in vivo outcomes, and to extrapolate across biologic systems. The abstract is online here, as of April 1, 2019, at Environmental Health Perspectives.


Low-cost, high-throughput

Yesterday brought the issuance of dozens of papers about the importance – or not – of p-values. That’s important news for trial lawyers, corporate officers, corporate directors, and risk managers. Persons in those roles (and others) are in for surprises if not aware of and ready for debates about and likely reduction in the litigation-related

Today, more and more studies involve gathering real world data as exposures occur, and then monitoring the health conditions of the monitored group. Studies of this sort sometimes are referred to as “exposomic studies.” New studies of this sort are underway in New Hampshire involving possible exposures to PFAs, and possible health. Interestingly, these studies

Three new justices joined the Florida Supreme Court early in 2019 due to retirements of others. The new justices all were appointed by a Republican governor; no doubt tort system defendants are hoping the new justices alter the existing legal balance in Florida. It will be interesting to see what happens. Evelyn Fletcher Davis provides

It’s world cancer day, a reminder of the biggest global terrorist and driver of much litigation.

The chart is from: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.